1 / 22

HIV Disease and Complications of Immunodeficiency

HIV Disease and Complications of Immunodeficiency. Chapter 29. HIV Disease. Symptoms Appear after incubation period of 6 days to 6 weeks Usually consist of fever, headache, sore throat, muscle aches, enlarged lymph nodes and generalized rash Some develop CNS symptoms

tori
Download Presentation

HIV Disease and Complications of Immunodeficiency

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. HIV Disease and Complications of Immunodeficiency • Chapter 29

  2. HIV Disease • Symptoms • Appear after incubation period of 6 days to 6 weeks • Usually consist of fever, headache, sore throat, muscle aches, enlarged lymph nodes and generalized rash • Some develop CNS symptoms • Range from moodiness and to seizures and paralysis • Symptoms constitute acute retroviral syndrome (ARS) • Typically subside in 6 weeks • Acute illness followed by asymptomatic period • Period may end with persistent enlargement of lymph nodes • Lymphadenopathy syndrome (LAS) • Immunodeficiency symptoms include fever, weight loss, fatigue and diarrhea • Referred to as AIDS-related complex (ARC)

  3. HIV Disease • Causative agent • In U.S and most other parts of the world disease caused by human immunodeficiency virus type 1 (HIV-1) • Belongs to lentivirus subgroup of retrovirus family • HIV-2 is similar in structure to HIV-1 but is antigenically distinct • Prominent cause of AIDS in parts of West Africa and India • Has appeared in the U.S. • Transmission is less efficient than HIV-1 • Disease progresses slower

  4. HIV Disease

  5. HIV Disease • Pathogenesis • HIV attacks a variety of cell types • Most critical are helper T cells • Viral gp120 attaches to CD4 cell surface receptor • Viral gp41 induces membrane fusion by interacting with chemokine cell surface receptor (CCR) • After entry, DNA copies of RNA genome produced using reverse transcriptase viral enzyme • DNA copy integrates and hides on host chromosome • In activated cells virus leaves cell genome and kills cell • Releases additional viruses to infect other cells • Macrophages have CD4 receptors • Infected macrophages are not killed but are impaired • Eventually immune system becomes too impaired to respond

  6. HIV Disease

  7. HIV Disease • Pathogenesis • Destruction of immune system helper T cells by HIV can occur via multiple mechanisms • Lysis following HIV replication • Attack by HIV-specific cytotoxic CD8+ T lymphocytes • CTL kill HIV-infected T cells • Antibody-dependent cellular cytotoxicity • Antibodies bind to gp120 and gp41 viral glycoproteins on infected T cells, facilitating the killing of those cells • Autoimmune process • Fusion of infected and uninfected cells • Facilitated by gp120 and gp41 on infected cells and CD4 and CCR on uninfected cells • Apoptosis • Accelerated in HIV infections

  8. HIV Disease • Pathogenesis • In nearly 80% of all cases immune system slowly loses ground to virus • Peripheral CD4+ count steadily falls to nearly 50 cell /µl • Symptoms usually appear when count falls below 200 cells/µl • Atypical progression of disease occurs in roughly 10% of infected individuals • Disease progresses rapidly to AIDS within a few months • Another 5% - 10% do not experience a fall in CD4+ cells • Maintain high levels of antibodies and CD8+ cells • Disease progresses slowly • May be AIDS-free for 20 years

  9. HIV Disease • Epidemiology • Indiscriminate sexual intercourse major factor in spread • Promiscuous homosexual men most common • Survey indicates before arrival of AIDS 33% to 40% of homosexual men had more than 500 lifetime partners • Next most important mode of transmission is through blood and blood products • By 1984 over 50% of hemophiliacs in U.S. were infected • 10% - 20% of their sexual partners were HIV positive • Today, blood transmission is usually I.V. drug use (needle-sharing) • Third most important mode of transmission is mother to infant • One in 10 pregnant HIV-positive women will miscarry • Of live-born infants, 15% - 40% will develop AIDS • Breast feeding carries significant risk of mother-infant transmission

  10. HIV Disease • Prevention and Treatment • No approved vaccine • Most people infected are unaware • Virus on surfaces can be inactivated with commercially available disinfectants and heat at 56°C for more that 30 minutes • Knowledge of transmission greatest tool for control • Use of condoms not 100% effective but have been shown to decrease transmission • Avoidance of practices that favor HIV transmission

  11. HIV Disease • Prevention and Treatment • Treatment directed at “cocktails” of drugs • Combination of reverse transcriptase inhibitors and protease inhibitors • HAART = highly active antiretroviral therapy • Reverse transcriptase inhibitors fall into two categories • Nucleoside reverse transcriptase inhibitors • Zidovudine (AZT), stavudine (D4T) and lamivudine (3TC) • Non-nucleoside reverse transcriptase inhibitors • Nevirapine, efavirenz and delavirdine

  12. HIV Disease • Prevention and Treatment • Highly-Active Anti-Retroviral Therapy • Protease inhibitors • 6 in use • Act late in HIV replication to prevent packaging of viral proteins • HAART does not cure AIDS • Viremia becomes undetectable in approximately 50% of cases • Will reappear in absence of treatment • Many strains fail to respond to HAART due to resistance

  13. HIV Disease • HIV vaccine prospects • Currently no approved vaccines • In theory, vaccine could be used in two ways • Prevention vaccine • Immunize uninfected individuals against disease • Therapeutic vaccine • Boost immunity of those already infected • Successful vaccine must • produce both mucosal and blood stream immunity • get around HIV variability and stimulate cellular and humoral immunity

  14. HIV Disease • HIV vaccine prospects • Attenuated agent must not: • Be capable of turning into disease-causing strain • Be oncogenic • Stimulate an autoimmune response • Cause production of “enhancing” antibodies that could aid in the passage of HIV into the body’s cells • Finally, vaccine should induce neutralizing antibodies against free virions and prevent direct spread of HIV from cell to cell • Vaccine trial in humans has been undertaken for at least 10 experimental vaccines • All have failed and prospects do not look favorable

  15. Kaposi’s Sarcoma • Unusual tumor arising from blood or lymphatic vessels in multiple locations • Common in men of Mediterranean and Eastern European descent • Not as a sign of immunodeficiency • Tumor began to appear in young men with HIV • 2000 time higher than period before HIV • So common among AIDS patients became AIDS-defining condition

  16. Kaposi’s Sarcoma • Human herpesvirus-8 (HHV-8) detected in sarcomas • Virus infects endothelial cells that line blood and lymphatic vessels • Persists mostly in latent form • Presence of virus associate with two dramatic changes that result in tumor formation: • Cells assume spindle shape and proliferate • Extensive formation of new blood vessels occurs

  17. B-Lymphocytic Tumors of the Brain • B-cell lymphomas 60 to 100 times more common in AIDS patients compared to general public • Intense, sustained replication of lymphoid cells is constant feature of HIV • Lymph node enlargement reflects proliferation of lymphoid cells in response to high level unregulated cytokine release • Replication of T cells occurs to replace those destroyed by HIV • Epstein-Barr virus plays roll in B-cell lymphomas associated with AIDS • Lymphomas rarely occur in brain except with AIDS patients

  18. Pneumocystosis • Symptoms • Typically begins slowly with gradually increasing shortness of breath and rapid breathing • Fever is usually slight or absent • 50% of patients have non-productive cough • Skin and mucous membranes becomes dusky • Due to poor oxygenation of blood

  19. Pneumocystosis • Causative agent - Pneumocystis carinii • Tiny fungus belonging to phylum Ascomycota • Formerly considered a protozoan • Differs from many fungi in cell wall components • Consequently resistant to many fungal medications • Pathogenesis • Spores of organism are inhaled into lung • Attach to alveolar walls • Alveoli fill with fluid, mononuclear cells and organisms • Alveolar walls become thickened and scarred • Interferes with free passage of oxygen

  20. Pneumocystosis • Epidemiology • Widespread among animals including dogs, cats, horses and rodents • Serological testing indicates almost all children are infected by age two and a half • Infection is asymptomatic and generally eliminated in a year • Source of transmission in humans is unknown • Most cases of pneumocystosis occur in immunocompromised • Epidemics among hospitalized malnourished infants and elderly nursing home residents suggest airborne spread

  21. Pneumocystosis • Prevention and Treatment • Disease used to occur in four-fifths of AIDS patients • Was leading cause of death • Disease largely preventable with regular doses of trimethoprim-sulfamethoxazole (TxS) • Among the best medication for treating disease along with oxygen support • Reduced mortality rate from nearly 100% to 30% • After treatment patient must receive preventive medication indefinitely until rise in CD4+ T cells above 200 cells/μl

  22. Other Common Opportunistic Infections of AIDS • Toxoplasmosis (Toxoplasma gondii) • Herpesviruses • Herpes simplex viruses 1&2 • Cytomegalovirus • Mycobacterium avis (TB-like disease)

More Related